Stempoint Capital’s Denali Therapeutics DNLI Stock Holding History

Stempoint Capital’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-426,561	Closed	-$8.19M	–	89
2026 Q1	$8.19M	Buy	426,561 +7,503	+2%	+$149K	1.57%	22
2025 Q4	$6.92M	Sell	419,058 -1,315,601	-76%	-$22.2M	1.19%	24
2025 Q3	$25.2M	Buy	1,734,659 +1,026,744	+145%	+$14.8M	5.05%	5
2025 Q2	$9.9M	Buy	707,915 +40,837	+6%	+$575K	3.18%	11
2025 Q1	$9.07M	Buy	667,078 +82,750	+14%	+$1.59M	2.89%	12
2024 Q4	$11.9M	Buy	584,328 +302,278	+107%	+$7.74M	2.97%	9
2024 Q3	$8.22M	Buy	282,050 +31,040	+12%	+$769K	2.46%	14
2024 Q2	$5.83M	Buy	+251,010	New	+$4.82M	1.71%	19

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Stempoint Capital's DNLI Position: Q2 2026 in Review

Stempoint Capital sold out of Denali Therapeutics (DNLI) in Q2 2026, closing a stake of 426,561 shares — an estimated $8.19M sold.

Stempoint Capital first reported a position in DNLI in Q2 2024 and held it in 8 quarters. The position peaked at $25.2M in Q3 2025. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Stempoint Capital reported no remaining Denali Therapeutics position as of Q2 2026 after selling out during the quarter.
Stempoint Capital sold 426,561 Denali Therapeutics shares in Q2 2026, an estimated $8.19M.
Stempoint Capital first reported a position in Denali Therapeutics in Q2 2024 and held it in 8 quarters.
Stempoint Capital's Denali Therapeutics position peaked at $25.2M in Q3 2025.
294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.